Shop
eStoreRx™
Online Supplement Dispensary
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
Biotics Research is proud to expand our commitment to education with the Wellness Unfiltered Pro Podcast. Each episode delves into key health topics and the clinical applications of our premier products. Through candid, insightful conversations, our team offers practical guidance to keep you informed and empowered as a healthcare professional.
December 20 2024
The British Journal of Sports Medicine recently published a systematic review that analyzed the effects of postpartum exercise on maternal postpartum ...
Results of a single-blind placebo-controlled trial were recently published in BMC Pediatrics, indicating a beneficial effect of supplementation with vitamin E enriched with tocotrienol (TRF) for children with obesity and non-alcoholic fatty liver disease (NAFLD). This follows a 24-week controlled trial among adults, in which delta-tocotrienol was shown to improve markers of steatosis and hepatocellular injury, including the fatty liver index (FLI), homeostasis model of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hs-CRP), malondialdehyde (MDA), alanine transaminase (ALT), and aspartate transaminase (AST).
In this trial, 32 Malaysian children (mean age of approximately 12 years old) received either placebo or a daily dose of 50 mg of vitamin E isomers (comprised 7.4 mg δ-tocotrienol, 2.02 mg β-tocotrienol, 22.3 mg γ-tocotrienol, 18.28 mg α-tocotrienol, and 17.1 mg α-tocopherol) for 6 months, with the trial’s primary outcome defined as the mean difference in hepatic steatosis as evaluated by the controlled attenuated parameter (CAP). Multiple secondary outcomes included fibrosis scores and biochemical assessments of inflammation, DNA damage, etc.
Among the 29 children who completed the trial, those who received TRF had significantly lower apolipoprotein-A1 (ApoA1) and aspartate aminotransferase (AST) levels after 6 months compared to baseline. Additionally, significant reductions were observed in pro-inflammatory cytokines (IL-6 and TNF-1) as well as DNA damage parameters (comet assay) after TRF supplementation. No differences were observed between groups for multiple secondary outcomes, including ALT, fasting blood glucose, α-2-M, GGT, haptoglobin, total bilirubin, and triglycerides. While a slight reduction in CAP was observed in the placebo group (perhaps due to behavioral changes), the decrease in the TRF group was not significant. No adverse effects were observed with TRF, suggesting that it may have a valuable role as a supportive and safe therapy for pediatric NAFLD, helping with oxidative damage and a healthy inflammatory response.
Submit this form and you'll receive our latest news and updates.
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment